購物車 
-
4'-乙炔基-2'-脫氧腺苷
- names：
4'-Ethynyl-2'-deoxyadenosine
- CAS號：
306305-07-7
MDL Number： - MF(分子式)： C12H13N5O3 MW(分子量)： 275.26
- EINECS: Reaxys Number:
- Pubchem ID:481527 Brand:BIOFOUNT
| 貨品編碼 | 規格 | 純度 | 價格 (￥) | 現價(￥) | 特價(￥) | 庫存描述 | 數量 | 總計 (￥) |
|---|---|---|---|---|---|---|---|---|
| YZM000681-250mg | 250mg | >97% | ￥ 0.00 | ￥ 0.00 | Backorder | ￥ 0.00 | ||
| YZM000681-100mg | 100mg | >97% | ￥ 0.00 | ￥ 0.00 | Backorder | ￥ 0.00 |
| 中文別名 | 4'-乙炔基-2'-脫氧腺苷(306305-07-7);4'-E-dA;（2R，3S，5R）-5-（6-氨基嘌呤-9-基）-2-乙炔基-2-（羥甲基）四氫呋喃-3-醇； |
| 英文別名 | 4'-Ethynyl-2'-deoxyadenosine(306305-07-7);Adenosine, 2'-deoxy-4'-C-ethynyl-;4'-Ethynyl-2'-deoxyadenosine;4'-ETHYNYL-2'-DEOXYADENOSINE; |
| CAS號 | 306305-07-7 |
| Inchi | InChI = 1S / C12H13N5O3 / c1-2-12（4-18）7（19）3-8（20-12）17-6-16-9-10（13）14-5-15-11（9） 17 / h1,5-8,18-19H，3-4H2，（H2,13,14,15）/ t7-，8 +，12 + / m0 / s1 |
| InchiKey | HMIGVKANVVLEOA-JOAULVNJSA-N |
| 分子式 Formula | C12H13N5O3 |
| 分子量 Molecular Weight | 275.26 |
| 溶解度Solubility | |
| 性狀 | 固體粉末Solid |
| 儲藏條件 Storage conditions | 請根據產品建議的存儲條件進行存儲,Please store the product under the recommended condition sin the description. |
4'-乙炔基-2'-脫氧腺苷(306305-07-7,4'-Ethynyl-2'-deoxyadenosine,4'-E-dA)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產生的廢棄物需分類存儲，并交于專業生物廢氣物處理公司處理，以免造成環境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tags:4'-E-dA試劑,4'-E-dA雜質,4'-E-dA中間體,4'-E-dA密度,4'-E-dA溶解度,4'-E-dA旋光度,4'-E-dA閃點,4'-E-dA熔點,4'-E-dA購買，4'-E-dA結構式，4'-E-dA熔點，
| 產品說明 | 4'-乙炔基-2'-脫氧腺苷(306305-07-7,4'-Ethynyl-2'-deoxyadenosine,4'-E-dA)是一種有效的核苷逆轉錄酶 (RT)的抑制劑,是一種有效的抗病毒藥物 |
| Introduction | 4'-乙炔基-2'-脫氧腺苷(306305-07-7,4'-Ethynyl-2'-deoxyadenosine,4'-E-dA)a nucleosidereverse transcriptase (RT)inhibitor, is an antiretroviral agent which is potent against drugesistant HIV variants, |
| Application1 | (306305-07-7)4'-Ethynyl-2'-deoxyadenosine (4'-E-dA)是一種有效的核苷逆轉錄酶 (RT)的抑制劑,是一種有效的抗病毒藥物,對耐藥HIV變異型具有較強的抑制作用，在MT-4細胞中，EC50值是 98 nM |
| Application2 | 4'-乙炔基-2'-脫氧腺苷(306305-07-7,4'-Ethynyl-2'-deoxyadenosine,4'-E-dA)with anEC50of 98 nM in MT cells for antiIV activity. |
| Application3 |
4'-乙炔基-2'-脫氧腺苷(306305-07-7,4'-Ethynyl-2'-deoxyadenosine,4'-E-dA)藥理學：
4'-乙炔基-2'-脫氧腺苷（4'-E-dA），一種核苷逆轉錄酶（RT）抑制劑，是一種抗逆轉錄病毒藥物，對耐藥性HIV變異體有效，在MT-中的EC50為98 nM。 4個細胞具有抗HIV-1活性。
| 警示圖 | |
| 危險性 | warning |
| 危險性警示 | Not available |
| 安全聲明 | H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害 |
| 安全防護 | P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續沖洗+P337如果眼睛刺激持續+P2393獲得醫療建議/護理 |
| 備注 | 實驗過程中防止吸入、食入，做好安全防護 |
| Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor The Journal of biological chemis |
| 2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants The international journal of biochemistry & cell biology |
| 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity Chemical record (New York |
| Design, efficient synthesis, and anti-HIV activity of 4'-C-cyano- and 4'-C-ethynyl-2'-deoxy purine nucleosides Nucleosides, nucleotides & nucleic acids |
| Synthesis of 4'-C-ethynyl and 4'-C-cyano purine nucleosides from natural nucleosides and their anti-HIV activity Nucleosides, nucleotides & nucleic acids |
4'-乙炔基-2'-脫氧腺苷(306305-07-7,4'-Ethynyl-2'-deoxyadenosine,4'-E-dA)參考文獻：
1、4'-C-substituted-2'-deoxynucleosides: a family of antiretroviral agents which are potent against drug-resistant HIV variants H Ohrui 1, H Mitsuya
H Ohrui 1, H Mitsuya
Abstract In the past years, a variety of 4'-C-substituted-2'-deoxynucleosides (4'SdNs) were designed, synthesized, and examined as potential therapeutics against human immunodeficiency virus (HIV) infection and certain such analogues proved to exert potent activity against HIV-1 in vitro. Unlike currently available nucleoside reverse transcriptase (RT) inhibitors such as 3'-azido-3'-deoxythymidine (AZT), which have the 2',3'-dideoxy configuration and thereby cause DNA chain termination in the elongating proviral DNA, 4'SdNs do retain the 3'-alpha-OH moiety but also appear to work against retrovirus as proviral DNA chain terminators. Several 4'SdNs have been shown to be active against various laboratory and clinical HIV-1 strains including known drug-resistant HIV-1 variants. Among such 4'SdNs is 4'-azido-2'-deoxythymidine (4'-AZT) which exerts potent antiviral activity against wild type and AZT-resistant clinical HIV strains. More anti-HIV 4'SdNs have recently been reported including 4'-ethynylthymidine, 4'-ethynyl-2'-deoxy-D-ribofuranosyl-2,6-diaminopurine (4'-E-dDAP), 4'-ethynyl-2'-deoxyguanosine (4'-E-dG) and 4'-ethynyl-2'-deoxyadenosine (4'-E-dA). The latter three analogues are highly potent against HIV-1 and HIV-2 with EC50 values ranging from 0.0003 to 0.01 microM and have favorable cytotoxicity profiles with selective index (SI) values ranging from 975 to 2600. These 4'-ethynyl-2'-deoxynucleosides also exert potent activity against all known drug-resistant HIV-1 variants including the multi-dideoxynucleoside-resistant HIV and the variants with the 6-base pair inserts. Some of these compounds have favorable pharmacological properties and further development as potential therapeutics against HIV-1 infection is warranted.
2、Synthesis of nucleotide analogues, EFdA, EdA and EdAP, and the effect of EdAP on hepatitis B virus replication
Mai Kamata 1, Toshifumi Takeuchi 1, Ei Hayashi 1, Kazane Nishioka 1 2, Mizuki Oshima 1 2, Masashi Iwamoto 1 2, Kota Nishiuchi 1, Shogo Kamo 1, Shusuke Tomoshige 1, Koichi Watashi 1 2, Shinji Kamisuki 3, Hiroshi Ohrui 4, Fumio Sugawara 1, Kouji Kuramochi
Abstract 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) and 4'-ethynyl-2'-deoxyadenosine (EdA) are nucleoside analogues which inhibit human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. EdAP, a cyclosaligenyl (cycloSal) phosphate derivative of EdA, inhibits the replication of the influenza A virus. The common structural feature of these compounds is the ethynyl group at the 4'-position. In this study, these nucleoside analogues were prepared by a common synthetic strategy starting from the known 1,2-di-O-acetyl-D-ribofuranose. Biological evaluation of EdAP revealed that this compound reduced hepatitis B virus (HBV) replication dose-dependently without cytotoxicity against host cells tested in this study.
3、Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine
Karen A Kirby 1, Eleftherios Michailidis, Tracy L Fetterly, Musetta A Steinbach, Kamalendra Singh, Bruno Marchand, Maxwell D Leslie, Ariel N Hagedorn, Eiichi N Kodama, Victor E Marquez, Stephen H Hughes, Hiroaki Mitsuya, Michael A Parniak, Stefan G Sarafianos
Abstract Nucleos(t)ide reverse transcriptase inhibitors (NRTIs) form the backbone of most anti-HIV therapies. We have shown that 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) is a highly effective NRTI; however, the reasons for the potent antiviral activity of EFdA are not well understood. Here, we use a combination of structural, computational, and biochemical approaches to examine how substitutions in the sugar or adenine rings affect the incorporation of dA-based NRTIs like EFdA into DNA by HIV RT and their susceptibility to deamination by adenosine deaminase (ADA). Nuclear magnetic resonance (NMR) spectroscopy studies of 4'-substituted NRTIs show that ethynyl or cyano groups stabilize the sugar ring in the C-2'-exo/C-3'-endo (north) conformation. Steady-state kinetic analysis of the incorporation of 4'-substituted NRTIs by RT reveals a correlation between the north conformation of the NRTI sugar ring and efficiency of incorporation into the nascent DNA strand. Structural analysis and the kinetics of deamination by ADA demonstrate that 4'-ethynyl and cyano substitutions decrease the susceptibility of adenosine-based compounds to ADA through steric interactions at the active site. However, the major determinant for decreased susceptibility to ADA is the 2-halo substitution, which alters the pKa of N1 on the adenine base. These results provide insight into how NRTI structural attributes affect their antiviral activities through their interactions with the RT and ADA active sites.
- 相關產品
-
< >
- 推薦產品
-
< >
- 最新產品
-
< >
新聞
怎么做細胞爬片免疫組化染色實驗
細胞爬片免疫組化染色，是通過細胞爬片是讓玻片浸在細胞培養基內，細胞在玻片上生長，主要用于組織學，免疫組織化學...
2020/7/20 22:04:33
提取病毒RNA的實驗方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
細胞培養耗材技術領先性
細胞培養板行業面臨的核心痛點是：常規TC處理后表面親水角隨時間衰減，影響長期培養穩定性，BIOFOUNT高分...
2026/4/28 15:12:51
細胞培養耗材關鍵性能
細胞培養板的水接觸角作為表面潤濕性的核心指標，直接影響細胞貼壁、增殖、分化及功能表達，其中40°（低接觸角/...
2026/4/28 14:52:44
chelex 100樹脂國產替代之路-BIOFOUNT范德生物
Chelex 100螯合離子交換樹脂對銅、鐵和其他重金屬?的偏好顯著高于對鈉、鉀等一價陽離子的偏好。它對二價...
2025/11/4 14:22:46
9月開學季——助研新學期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實驗室封口膜：技術與國際市場的雙重突破
在實驗室耗材領域，封口膜是保障實驗準確性與穩定性的關鍵產品之一。近年來，Waxfilm?實驗室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實驗室封口膜的5大突破
Waxfilm實驗室封口膜作為生物功能膜領域的國產技術突破和品牌突破，是生物領域中國技術發展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優缺點
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優缺點。本文主要介紹聚酯...
2023/7/28 10:43:09
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個重要環節，也是最容易被忽視的--芯片鍵合。其中一個重要因素是：微流控...
2023/7/27 12:44:28
